Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
